Similarly, in a randomized, phase III trial including 758 women with node-positive, HER2-low breast cancer in the adjuvant setting, no significant difference in DFS was observed between NP-S and placebo arms (HR 1.56, 95% CI, 0.96–2.55, p = 0.07) [81]. This evidence concerns the gene ERBB2 and breast cancer.